LY-2950913

LY-2950913 is an investigational pharmaceutical compound originally discovered and developed by Eli Lilly as part of its biologics and antibody‑based pipeline, and subsequently licensed to Transcenta Holding (through its predecessor MabSpace) as one of several “Licensed Compounds” for further development in China and potentially globally.[1][3][4][7][9][12] Public disclosures from Transcenta’s filings identify LY-2950913 only by code number within a group of in‑licensed Eli Lilly assets (together with blosozumab/LY‑2541546 and LY‑3108653) without providing target, modality, indication, or clinical‑stage details, and external drug databases list LY‑2950913 as a preclinical, non‑approved drug with no mechanism or indication specified.[1][11] As of the latest available reports, LY‑2950913 remains an early‑stage research asset without publicly disclosed molecular target, mechanism of action, or specific therapeutic area, beyond its positioning in Transcenta’s broader biologics and oncology/immune‑related R&D portfolio.[1][3][4][7][9][11][12]